Fig. 10From: Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling3D and 2D Interactions of designed compound 6 with the active site of the EGFR receptorBack to article page